Core Insights - CRISPR Therapeutics and Sirius Therapeutics have formed a strategic partnership to co-develop and commercialize SRSD107, a long-acting Factor XI (FXI) small interfering RNA (siRNA) for thromboembolic disorders [1][2] - SRSD107 has shown promising results in Phase 1 clinical trials, achieving over 93% reduction in FXI activity and more than twofold increase in activated partial thromboplastin time (aPTT), with effects lasting up to 6 months post-dosing [1][3] - The collaboration includes an upfront payment of $25 million in cash and $70 million in equity from CRISPR to Sirius, with a 50-50 cost and profit-sharing structure for SRSD107 [1][8] Company Overview - CRISPR Therapeutics is focused on creating transformative gene-based medicines and has a diverse portfolio across various disease areas, including cardiovascular diseases [10] - Sirius Therapeutics is a clinical-stage biotech company developing innovative siRNA therapies, with SRSD107 being its most advanced product targeting thromboembolic disorders [17][18] Clinical Development - The clinical program for SRSD107 includes two Phase 1 trials demonstrating safety and robust pharmacodynamic effects, with a Phase 2 trial planned to evaluate its efficacy in preventing venous thromboembolism (VTE) in total knee arthroplasty patients [3][7] - SRSD107 is designed to selectively inhibit FXI, aiming to reduce thrombotic events while minimizing bleeding risks, offering a differentiated approach compared to existing therapies [2][16] Market Potential - Thromboembolic disorders are a significant global health issue, affecting millions and representing a substantial unmet medical need [2][15] - The addressable patient population for SRSD107 includes those with atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and other conditions where existing therapies pose bleeding risks [2][3]

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Investor Conferen ...

VolitionRX (VNRX) Q1 2025 Earnings Call May 16, 2025 08:30 AM ET Company Participants Louise Batchelor Day - Group Chief Marketing & Communications OfficerTerig Hughes - CFOCameron Reynolds - President and Chief Executive Officer Conference Call Participants Ilya Zubkov - Senior Equity Research AnalystSteven Ralston - Director & Senior Analyst Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx's Rx Limited First Quarter twenty twenty five Earnings Conference Call. ...

Core Insights - The Blood Pressure Solution is a comprehensive lifestyle program designed to help individuals manage high blood pressure through natural means, focusing on diet, exercise, and stress management rather than solely relying on medication [2][94][97] - Developed by Dr. Marlene Merritt, the program emphasizes understanding the root causes of hypertension and provides actionable strategies for long-term cardiovascular health [9][23][72] Group 1: Program Overview - The program combines dietary education, stress management techniques, and evidence-informed lifestyle changes to address hypertension [2][4][10] - It offers a structured, easy-to-follow format that appeals to individuals seeking a holistic approach to heart health [2][4][30] - The Blood Pressure Solution is positioned as an alternative to conventional treatments, focusing on sustainable, drug-free strategies [2][44][45] Group 2: Root Causes of Hypertension - Hypertension is often driven by modifiable lifestyle and environmental factors, including poor diet, sedentary habits, and chronic stress [12][13][14] - Chronic inflammation and insulin resistance are critical drivers of high blood pressure, which the program addresses through dietary changes [15][16][32] - The program recognizes the impact of stress on blood pressure and incorporates stress-reduction strategies as a core component [19][20][21] Group 3: Nutritional Focus - The Blood Pressure Solution emphasizes the importance of nutrition in managing blood pressure, advocating for potassium-rich, anti-inflammatory foods [32][33][34] - Key dietary components include whole foods, healthy fats, and complex carbohydrates, which support cardiovascular wellness [42][96] - The program also includes guidance on herbal supports known to promote heart health, such as garlic and hibiscus [38][40][41] Group 4: Lifestyle Integration - The program encourages simple, non-intimidating daily activities to enhance cardiovascular health, such as walking and stretching [18][65] - Stress management and sleep hygiene are integrated into the program to promote overall wellness [66][70] - Users are encouraged to track their progress and make small, consistent changes to their daily routines [67][80] Group 5: Purchasing and Support - The Blood Pressure Solution is available exclusively through its official website, ensuring authenticity and access to customer support [51][52] - The program is offered as a one-time purchase, making it a budget-friendly option compared to ongoing medication costs [50][57] - A satisfaction guarantee is provided, allowing users to request a refund if the program does not meet their expectations [58][98]

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three new non-executive employees in connection with the commencement of their employment. The stock options have an exerci ...

Company Overview - Veri Medtech Holdings, Inc. (Stock Ticker Symbol: "VRHI") is a healthcare technology platform that generated $3,308,297 in revenue during Q1 2025, with total sales revenue reaching up to $100 million since its inception in 2017 [1] - The company focuses on alternative medicine, personalized diagnostics, and wellness medication on demand, leveraging telehealth infrastructure and scalable digital systems to meet the growing demand for accessible healthcare [2] Key Accomplishments - The company successfully relaunched its Veriheal.com platform and DosePop.com, enhancing its telehealth technology diversification strategy [1][3] - Veri Medtech has achieved significant milestones, including reaching up to 400,000 patients and 400 physicians [3] Market Position and Growth Potential - The global telemedicine market was valued at approximately $114.98 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.96% from 2024 to 2030, driven by increasing healthcare consumerism and provider adoption [2] - The company is strategically positioned to capture market share in the telehealth sector, with a focus on its Infinite Wellness Loop, which connects patients, platforms, and physicians 24/7 [1]

Core Insights - Adial Pharmaceuticals has made significant progress in the first quarter of 2025, particularly in advancing its lead investigational drug AD04 for Alcohol Use Disorder (AUD) [2] - The company successfully completed a pharmacokinetics bridging study, confirming favorable bioavailability of AD04, and has begun manufacturing clinical trial supplies [2] - Regulatory alignment with the FDA has been achieved, supporting a streamlined path for the upcoming Phase 3 clinical trial [2] - Adial has strengthened its intellectual property portfolio with multiple granted patents related to AD04 [5] Financial Results - As of March 31, 2025, cash and cash equivalents were $2.4 million, down from $3.8 million as of December 31, 2024 [12] - Research and development expenses increased by approximately $293 thousand (65%) compared to the same period in 2024, driven by increased CMC expenses and consulting [12] - General and administrative expenses rose by approximately $129 thousand (9%) due to higher compensation and consulting [12] - The net loss for the first quarter of 2025 was $2.2 million, a decrease from a net loss of $6.5 million in the same quarter of 2024 [12] Strategic Developments - Adial received a six-figure milestone payment from Adovate, LLC, following the start of a Phase 1 clinical trial for an asthma compound [3] - The company is eligible for over $50 million in commercial milestone payments and an additional $11 million in development and approval milestone payments for the first three compounds [4] - Adial retains over a 10% equity stake in Adovate, allowing participation in the long-term upside as the asthma candidate progresses [4] Intellectual Property - A new patent was issued covering the administration of AD04 as a precision medicine approach for patients with specific genetic markers [5] Future Outlook - The company is preparing for an End of Phase 2 meeting with the FDA in July to finalize the Phase 3 trial design [2][13] - There is confidence in advancing AD04 through late-stage development, with potential applications for other addictive disorders such as Opioid Use Disorder, gambling, and obesity [9][13]

WEST PALM BEACH, FL, May 15, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the "Company") (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its financial results for the three months ended March 31, 2025. Financial Highlights for Q1 2025: The strong year-over-year growth was driven by a diversified revenue base including: QHSLab, Inc. (OTCQB: USAQ) is a medical device company prov ...

– SLE and LN registrational discussions with FDA anticipated in 3Q25; systemic sclerosis registrational discussions with FDA anticipated in 4Q25 – – New clinical data on rese-cel in myositis, SLE / LN and systemic sclerosis to be presented in three oral sessions at the EULAR 2025 Congress in June – – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – As of March 31, 2025, the Company had cash and cash equivalents of $131.8 million, per our Form 10-Q being filed ...

Core Viewpoint - Cyclacel Pharmaceuticals is focusing on the development of its plogosertib clinical program while undergoing significant operational changes due to the liquidation of its UK subsidiary, Cyclacel Limited, which has impacted its financial results and strategic direction [2][4][7]. Financial Highlights - As of March 31, 2025, cash and cash equivalents increased to $3.5 million from $3.2 million as of December 31, 2024 [3]. - Net cash used in operating activities for the first quarter of 2025 was $3.3 million, with current cash resources expected to fund planned programs into the second quarter of 2025 [3]. - Research and development expenses were $0.8 million for the first quarter of 2025, a decrease from $2.8 million in the same period of 2024, primarily due to the cessation of expenditures related to the transcriptional regulation program following the liquidation of Cyclacel Limited [4]. - General and administrative expenses rose to $4.2 million for the first quarter of 2025, up from $1.6 million in the same period of 2024, attributed to one-time costs associated with the change of control [5]. - The company reported a net loss of $0.1 million for the first quarter of 2025, a significant improvement compared to a net loss of $2.9 million in the same period of 2024 [7]. Strategic Developments - The company has decided to focus solely on the plogosertib program and has repurchased related assets for approximately $0.3 million to enhance the development of an alternative salt, oral formulation with improved bioavailability [2]. - Following the liquidation of Cyclacel Limited, the company lost operational control over the subsidiary, leading to a gain on deconsolidation of approximately $5.0 million, which increased stockholders' equity [2][6]. - The company is exploring strategic alternatives to ensure its continued operation, including raising additional debt or equity financing or pursuing a merger or acquisition [2]. Research and Development Focus - Cyclacel is concentrating on the plogosertib program, which is a PLK1 inhibitor being evaluated for treating solid tumors and hematological malignancies [8]. - The company has ceased expenditures related to the fadraciclib program due to the liquidation of Cyclacel Limited, which has allowed for a reallocation of resources towards plogosertib [4][6]. Summary of Financial Performance - Total operating expenses for the first quarter of 2025 were $5.0 million, compared to $4.4 million in the same period of 2024 [11]. - The company reported total other income of $5.0 million for the first quarter of 2025, primarily due to the gain on deconsolidation of the UK subsidiary [6]. - The total assets as of March 31, 2025, were $3.7 million, a decrease from $4.1 million as of December 31, 2024, reflecting the impact of the subsidiary's liquidation [12][13].